激素受体阳性HER2阴性乳腺癌的分子分类
Xi Jin1, Yi-Fan Zhou1, Ding Ma1
1Key Laboratory of Breast Cancer, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
研究人员确定了四种激素受体阳性 (HR+) /人表皮生长因子受体2-阴性 (HER2-) 乳腺癌的分子亚型. 这种分类有助于开发针对内分泌疗法耐药性和远程复发的向疗法.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 精准医学是一门精准的医学.
背景情况:
- 激素受体阳性 (HR+) /人表皮生长因子受体2-阴性 (HER2-) 乳腺癌是最常见的类型.
- 内分泌疗法耐药性和远程复发是管理这种亚型的重大挑战.
- 精确的分子分类对于有效的个性化治疗策略至关重要.
研究的目的:
- 在HR+/HER2-乳腺癌中确定分子亚型.
- 研究已识别的亚型的独特生物和临床特征.
- 探索潜在的亚型特定的治疗方法和诊断工具.
主要方法:
- 建立一个大规模的多omics队列 (579名患者).
- 四种分子亚型的识别和表征:正规的光,免疫,增殖和受体氨酸激酶 (RTK) 驱动.
- 使用数字病理学开发卷积神经网络模型用于亚型分类.
主要成果:
- 确定了HR+/HER2-乳腺癌的四种不同的分子亚型.
- 亚型具有独特的生物学和临床特征,影响治疗策略.
- 由于RTK通路激活,RTK驱动的亚型显示出不良结果.
- 具有丰富免疫细胞的免疫原子类型可能受益于免疫检查点治疗.
结论:
- HR+/HER2-乳腺癌的分子分类显示出显著的异质性.
- 特定于亚型的治疗策略,包括免疫检查点治疗免疫原性亚型,是有希望的.
- 使用人工智能的基于数字病理的分类为临床翻译和精确治疗提供了潜力.
更多相关视频
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
相关概念视频
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Types of Hormones
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Intracellular Hormone Receptors
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
